Pagano E, Romano B, Izzo AA, Borrelli F (2018) The clinical efficacy of curcumin-containing nutraceuticals: an overview of systematic reviews
& Naesby, M
Gastrointestinal issues: Severe gastrointestinal adverse reactions have been reported
Weight Loss Clinical Trial Results In Phase 2 clinical trials: Participants receiving 12 mg experienced up to 24.2% average body weight loss at 48 weeks Additional studies reported up to 28.7% weight reduction at 68 weeks Higher doses (8 mg and 12 mg) demonstrated the most significant results These findings suggest Retatrutide may outperform current GLP-1 therapies and dual-agonist medications in terms of total weight loss
If you are taking compounded tirzepatide , the sulfur burp experience tends to be similar to brand-name formulations, since the active ingredient and its effect on gastric emptying remain the same regardless of the source
Severe hypoglycaemia requiring third-party assistance mandates stopping driving and notifying the DVLA Patients should discuss these risk factors with their diabetes care team, who can provide individualised advice on medication timing, dosing adjustments, and blood glucose monitoring strategies to minimise hypoglycaemia risk whilst maintaining effective glycaemic control
